Absence of c-kit gene mutations in gastrointestinal stromal tumours from neurofibromatosis type I patients

Journal of Pathology

Volumn 202, Issue 1, 2004, Pages 80-85

  Kinoshita, Kazuo ^a   Hirota, Seiichi ^b   Isozaki, Koji ^a   Ohashi, Akiko ^b   Nishida, Toshirou ^b   Kitamura, Yukihiko ^b   Shinomura, Yasuhisa ^a   Matsuzawa, Yuji ^a  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

c kit gene mutation; Gastrointestinal stromal tumour; Neurofibromatosis type 1; NF1 gene mutation

Indexed keywords

COMPLEMENTARY DNA; GENOMIC DNA; NEUROFIBROMIN; STEM CELL FACTOR;

ARTICLE; CANCER RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DNA EXTRACTION; DNA SYNTHESIS; EXON; GASTROINTESTINAL STROMAL TUMOR; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC CODE; HETEROZYGOSITY; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; NEUROFIBROMATOSIS; PRIORITY JOURNAL; RNA EXTRACTION; SEQUENCE ANALYSIS;

BASE SEQUENCE; DNA, NEOPLASM; EXONS; GASTROINTESTINAL NEOPLASMS; GENES, NEUROFIBROMATOSIS 1; HETEROZYGOTE; HUMANS; IMMUNOHISTOCHEMISTRY; MUTATION; NEUROFIBROMATOSIS 1; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS C-KIT; STROMAL CELLS;

EID: 0346025449     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1487     Document Type: Article

References (43)

1. Fishman AP. Gastrointestinal tract. In Ackerman's Surgical Pathology (8th edn), Rosai J (ed). Mosby: St Louis, 1996; 645-647.
2. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279: 577-580.
3. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 1998; 152: 1259-1269.
4. Sircar K, Hewlett BR, Huizinga JD, Chorneyko K, Berezin I, Riddell RH. Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors. Am J Surg Pathol 1999; 23: 377-389.
5. Besmer P, Murphy JE, George PC, et al. A new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene family. Nature 1986; 320: 415-421.
6. Chabot B, Stephenson DA, Chapman VM, Besmer P, Bernstein A. The proto-oncogene c-kit encoding a transmembrane tyrosine kinase receptor maps to the mouse W locus. Nature 1988; 335: 88-89.
7. Geissler EN, Ryan MA, Housman DE. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 1988; 55: 185-192.
8. Williams DE, Eisenman J, Baird A, et al. Identification of a ligand for the c-kit proto-oncogene. Cell 1990; 63: 167-174.
9. Taniguchi M, Nishida T, Hirota S, et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297-4300.
10. Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002; 122: 1493-1499.
11. Kinoshita K, Isozaki K, Hirota S, et al. c-kit gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumors. J Gastroenterol Hepatol 2003; 18: 147-151.
12. Nishida T, Hirota S, Taniguchi M, et al. Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nature Genet 1998; 19: 323-324.
13. Hirota S, Okazaki T, Kitamura Y, O'Brien P, Kapusta L, Dardick I. Cause of familial and multiple gastrointestinal autonomic nerve tumors with hyperplasia of interstitial cells of Cajal is germline mutation of the c-kit gene. Am J Surg Pathol 2000; 24: 326-327.
14. Isozaki K, Terris B, Belghiti J, Schiffmann S, Hirota S, Vanderwinden JM. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol 2000; 157: 1581-1585.
15. Hirota S, Nishida T, Isozaki K, et al. Familial gastrointestinal stromal tumors associated with dysphagia and novel type germline mutation of KIT gene. Gastroenterology 2002; 122: 1493-1499.
16. Cawthon RM, Weiss R, Xu GF, et al. A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations. Cell 1990; 62: 193-201.
17. Viskochil D, Buchberg AM, Xu G, et al. Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell 1990; 62: 187-192.
18. Wallace MR, Marchuk DA, Andersen LB, et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science 1990; 249: 181-186.
19. Xu GF, O'Connell P, Viskochil D, et al. The neurofibromatosis type 1 gene encodes a protein related to GAP. Cell 1990; 62: 599-608.
20. Huson S, Hughes R. The Neurofibromatoses: a Clinical and Pathogenetic Overview. London: Chapman and Hall Medical, 1994.
21. National Institute of Health Consensus Development Conference: Neurofibromatosis conference statement. Arch Neurol 1988; 45: 575-578.
22. Thomson SA, Fishbein L, Wallace MR. NF1 mutations and molecular testing. J Child Neurol 2002; 17: 555-561; discussion 571-572, 646-651.
23. Huson SM, Harper PS, Compston DA. Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales. Brain 1988; 111: 1355-1381.
24. Riccardi VM. Von Recklinghausen neurofibromatosis. N Engl J Med 1981; 305: 1617-1627.
25. Fuller CE, Williams GT. Gastrointestinal manifestations of type 1 neurofibromatosis (von Recklinghausen's disease). Histopathology 1991; 19: 1-11.
26. Hochberg FH, Dasilva AB, Galdabini J, Richardson EP Jr. Gastrointestinal involvement in von Recklinghausen's neurofibromatosis. Neurology 1974; 24: 1144-1151.
27. Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997; 79: 2125-2131.
28. Min KW, Balaton AJ. Small intestinal stromal tumors with skeinoid fibers in neurofibromatosis: report of four cases with ultrastructural study of skeinoid fibers from paraffin blocks. Ultrastruct Pathol 1993; 17: 307-314.
29. Ishida T, Wada I, Horiuchi H, Oka T, Machinami R. Multiple small intestinal stromal tumors with skeinoid fibers in association with neurofibromatosis 1 (von Recklinghausen's disease). Pathol Int 1996; 46: 689-695.
30. Li Y, Bollag G, Clark R, et al. Somatic mutations in the neurofibromatosis 1 gene in human tumors. Cell 1992; 69: 275-281.
31. Hirota S, Ito A, Nagoshi J, et al. Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab Invest 1995; 72: 64-69.
32. Chirgwin JM, Przybyla AE, MacDonald RJ, Rutter WJ. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 1979; 18: 5294-5299.
33. Chen H, Hirota S, Isozaki K, et al. Polyclonal nature of diffuse proliferation of interstitial cells of Cajal in patients with familial and multiple gastrointestinal stromal tumours. Gut 2002; 51: 793-796.
34. Messiaen LM, Callens T, Mortier G, et al. Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects. Hum Mutat 2000; 15: 541-555.
35. Boguski MS, McCormick F. Proteins regulating Ras and its relatives. Nature 1993; 366: 643-654.
36. Legius E, Marchuk DA, Collins FS, Glover TW. Somatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesis. Nature Genet 1993; 3: 122-126.
37. Maruta H, Burgess AW. Regulation of the Ras signalling network. Bioessays 1994; 16: 489-496.
38. Linnekin D. Early signaling pathways activated by c-Kit in hematopoietic cells. Int J Biochem Cell Biol 1999; 31: 1053-1074.
39. Ning ZQ, Li J, Arceci RJ. Signal transducer and activator of transcription 3 activation is required for Asp(816) mutant c-Kit-mediated cytokine-independent survival and proliferation in human leukemia cells. Blood 2001; 97: 3559-3567.
40. Ma Y, Zeng S, Metcalfe DD, et al. The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations. Blood 2002; 99: 1741-1744.
41. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
42. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
43. Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 2002; 33: 466-477.